[KU Leuven] is actually the most innovative university in Europe according to Reuters Rankings thanks to our academic paper publications, number of patents per year, and…
In Conversation
EU markets have an adoption rate of 50 to 90 per cent for biosimilars, and they are supported by EMA. Romania must follow suit if it…
The company is well-positioned for the future and artificial intelligence has been one of our strongest assets for decades
Focusing resource allocation in defined areas all along the value chain, from R&D to Sales & Marketing, is crucial in the pharma industry
[The Romanian] pricing policy ultimately inhibits new competitors from entering the market, or forces existing products out of it, which is detrimental to patients
We are delighted to see what is going on in the local Ministry of Health. They are one of our biggest supporters, they encourage us to…
My main advice would be to take the word “impossible” out of your vocabulary
In [Novo Nordisk's] own words: “APIGENEX is our VIP CRO in chemistry and pharmacology”
This market is very sensitive to constant improvement and developing a skillset; it rewards people who are serious about their career
The third pillar [of the Czech Innovation Strategy], dubbed Smart Marketing, is about changing the image of the Czech Republic from a low-cost manufacturing location to…
Between the ageing population and the cost of innovation which will continue to rise, the burden being put on healthcare will only become heavier
The main challenge in the region is its instability. In addition to the pain and difficulties for the people living in these countries, it brings volatility…
